BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Naderi, Ali ^a   Liu, Ji ^a   Hughes Davies, Luke ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; I KAPPA B ALPHA; LUCIFERASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BEX2; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; BEX2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NERVE PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FEEDBACK SYSTEM; GENE TARGETING; GENETIC CORRELATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; TRANSCRIPTION REGULATION; BREAST TUMOR; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE KINASE 4; MUTAGENESIS, SITE-DIRECTED; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 77952316747     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-111     Document Type: Article

References (40)

1. Naderi A, Teschendorff AE, Beigel M, Cariati M, Ellis IO, Brenton JD, Caldas C. BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res 2007, 67:6725-6736. 10.1158/0008-5472.CAN-06-4394, 17638883.
2. Naderi A, Liu J, Bennett IC. BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer 2010, 126:1596-1610.
3. Brown AL, Kay GF. Bex1, a gene with increased expression in parthenogenetic embryos, is a member of a novel gene family on the mouse X chromosome. Hum Mol Genet 1999, 8:611-619. 10.1093/hmg/8.4.611, 10072429.
4. Bernstein SL, Koo JH, Slater BJ, Guo Y, Margolis FL. Analysis of optic nerve stroke by retinal Bex expression. Mol Vis 2006, 1:147-155.
5. Hofsli E, Wheeler TE, Langaas M, Laegreid A, Thommesen L. Identification of novel neuroendocrine-specific tumour genes. Br J Cancer 2008, 99:1330-1339. 10.1038/sj.bjc.6604565, 2570516, 18827820.
6. Foltz G, Ryu GY, Yoon JG, Nelson T, Fashey J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z, et al. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 2006, 66:6665-6674. 10.1158/0008-5472.CAN-05-4453, 16818640.
7. Kim AJ, Lee CS, Schlessinger D. Bex3 associates with replicating mitochondria and is involved in possible growth control of F9 teratocarcinoma cells. Gene 2004, 343:79-89. 10.1016/j.gene.2004.08.031, 15563833.
8. Rohrs S, Dirks WG, Meyer C, Marschalek R, Scherr M, Slany R, Wallace A, Drexler HG, Quentmeier H. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol Cancer 2009, 8:86. 10.1186/1476-4598-8-86, 2770485, 19835597.
9. McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH. The LMO2 T-Cell Oncogene Is Activated via Chromosomal Translocations or Retroviral Insertion during Gene Therapy but Has No Mandatory Role in Normal T-Cell Development. Mol Biol Cell 2003, 23:9003-9013.
10. Han C, Liu H, Liu J, Yin K, Xie Y, Shen X, Wang Y, Yuan J, Qiang B, Liu YJ, Peng X. Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex. Nucleic Acids Res 2005, 33:6555-6565. 10.1093/nar/gki964, 1298925, 16314316.
11. Deng X, Gao F, May WS. Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 2009, 113:422-428. 10.1182/blood-2008-06-165134, 2615654, 18845789.
12. Tsuchiya A, Tashiro E, Yoshiro M, Imoto M. Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1in leptomycin B-inhibited cyclin D1expression. Oncogene 2007, 16:1522-1532.
13. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Sxzabo E, Zon LI, Kyriakis JM, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996, 380:75-79. 10.1038/380075a0, 8598911.
14. Grether-Beck S, Felsner I, Brenden H, Krutmann J. Mitochondrial Cytochrome c Release Mediates Ceramide-induced Activator Protein 2 Activation and Gene Expression in Keratinocytes. J Biol Chem 2003, 278:47498-47507. 10.1074/jbc.M309511200, 12952965.
15. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 2002, 64:963-970. 10.1016/S0006-2952(02)01161-9, 12213593.
16. Hu J, Haseebuddin M, Young M, Colbum NH. Suppression of p65 phosphorylation coincides with inhibition of IB polyubiquitination and degradation. Mol Carcinog 2005, 44:274-284. 10.1002/mc.20142, 16163708.
17. Demarchi F, Bertoli C, Greer PA, Schneider C. Ceramide triggers an NF-kappaB-dependent survival pathway through calpain. Cell Death Differ 2005, 12:512-522. 10.1038/sj.cdd.4401592, 15933726.
18. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991, 353:670-674. 10.1038/353670a0, 1922387.
19. Ruvolo PP. Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 2001, 15:1153-1160. 10.1038/sj.leu.2402197, 11480555.
20. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999, 18:6063-6070. 10.1038/sj.onc.1202989, 10557095.
21. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999, 18:188-197. 10.1093/emboj/18.1.188, 1171114, 9878062.
22. Seznec J, Weit S, Naumann U. Gene expression profile in a glioma cell line resistant to cell death induced by a the chimeric tumor suppressor-1 (CTS-1), a dominant-positive variant of p53 - the role of NF{kappa}B. Carcinogenesis 2010, 31:411-418. 10.1093/carcin/bgp319, 20015865.
23. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, Kiss R. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 2009, 11:485-496. 2671859, 19412433.
24. Jung EJ, Moon HG, Cho BI, Jeong CJ, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007, 120:2331-2338. 10.1002/ijc.22434, 17304502.
25. Manna SK, Sah NK, Aggarwal BB. Protein tyrosine kinase p56lck is required for ceramide-induced but not tumor necrosis factor-induced activation of NF-kappa B, AP-1, JNK, and apoptosis. J Biol Chem 2000, 275:13297-13306. 10.1074/jbc.275.18.13297, 10788436.
26. Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, Wang Y, Xia LP, Feng GK, Liu QQ, et al. The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene 2009, 28:886-898. 10.1038/onc.2008.441, 19060920.
27. Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, Resar LMS, Birrer MJ. HMG-I/Y is a c-Jun/Activator Protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2004, 2:305-314.
28. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor B and its significance in prostate cancer. Oncogene 2001, 20:7342-7351. 10.1038/sj.onc.1204926, 11704864.
29. Wang CY, Guttridge DC, mayo MW, Baldwin AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19:5923-5929. 84448, 10454539.
30. Huber MA, Denk A, Peter RU, Weber L, Kraut N, Wirth T. The IKK-2/Ikappa Balpha/NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice. J Biol Chem 2002, 277:1268-1275. 10.1074/jbc.M109358200, 11694538.
31. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Listanti MP, Pestell RG. c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 2010, 285:8218-8226. 10.1074/jbc.M110.100792, 20053993.
32. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007, 13:62-69. 10.1038/nm1519, 17159986.
33. Shen Q, Uray IP, Li Y, Krisko T, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2007, 27:366-377. 10.1038/sj.onc.1210643, 17637753.
34. Yang J, Fan GH, Wadzinski BE, Sakurai H, Richmond A. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem 2001, 276:47828-47833. 2665282, 11591705.
35. Barisic S, Strozyk E, Peters N, Walczak H, Kulms D. Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ 2008, 15:1681-1690. 10.1038/cdd.2008.98, 18583989.
36. Kins S, Kurosinski P, Nitsch RM, Gotz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 2003, 163:833-843. 1868255, 12937125.
37. Tan Y, Rouse J, Zhang A, Cariati S, Cohen P, Comb MJ. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 1996, 15:4629-4642. 452194, 8887554.
38. Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, Yuan G, Zhang H, Yu M, Hu M, et al. Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 2007, 7:145. 10.1186/1471-2407-7-145, 1959235, 17672916.
39. Begum N, Ragolia L. cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells. J Biol Chem 1996, 271:31166-31171. 10.1074/jbc.271.49.31166, 8940115.
40. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe JE, Robertson JE, Aparicio S, Ellis IO, Brenton JD, Caldas C. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 2007, 26:1507-1516. 10.1038/sj.onc.1209920, 16936776.